
FDA clears two sickle-cell gene therapies, including CRISPR ...
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.

Life sciences industry predictions 2024: Curavit
December is here; the end of 2023 fast approaches. For those operating in the life sciences sector, it’s all too clear that the time has come for 2024 industry predictions.

PharmStars digital health accelerator names fall 2023 grads
Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the latest crop focusing on digital innovations in

Spyre raises $180m to advance IBD antibody pipeline
At the start of this year, Aeglea BioTherapeutics was looking like it may go out of business.

On Pfizer’s initiative to return clinical trial data to pati...
The average dropout rate in clinical trials hovers at about 30%.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content

3rd Next Generation RNA Therapeutics Summit
Accelerate Next Generation RNAs into Safe & Effective Clinical Candidates with Therapeutic Potentials Across All Diseases by Overcoming Quality, Stability, & Large-Scale Manufacturi

2nd mRNA Process Development & Manufacturing Summit Europe
Enhance Speed, Purity & Scalability of Your Process Development & Manufacturing to Improve Functionality, Efficacy & Approval Rate of mRNA Drugs Across All Disease Indication

3rd mRNA Analytical Development Summit
180+ Technical mRNA Specialists | 35+ Expert Speakers | 2 Content Streams

6th Chronic Kidney Disease Drug Development Summit
The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of

5th Targeted Radiopharmaceuticals Summit Europe 2023
With the recent double whammy of Bayer and Novartis both strategically investing in Bicycle Therapeutics to develop radioconjugates for oncology targets; mergers, acquisitions and collabora